We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

54 hedge funds and large institutions have $45.9M invested in CASI Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 16

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.04% less ownership

Funds ownership: 1.24% → 1.2% (-0.04%)

9% less capital invested

Capital invested by funds: $50.2M → $45.9M (-$4.3M)

14% less funds holding

Funds holding: 63 → 54 (-9)

75% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 12

Holders
54
Holders Change
-9
Holders Change %
-14.29%
% of All Funds
1.2%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
22
Reduced
16
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WSCM
Wellington Shields Capital Management
New York
+$1.09M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.07M
3
WSC
Wellington Shields & Co
New York
+$699K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$287K
5
AA
ALPS Advisors
Colorado
+$254K

Top Sellers

Rank Fund Capital Flow
1
RA
Royce & Associates
New York
-$368K
2
California Public Employees Retirement System
California Public Employees Retirement System
California
-$210K
3
PA
Perceptive Advisors
New York
-$204K
4
Deutsche Bank
Deutsche Bank
Germany
-$181K
5
Barclays
Barclays
United Kingdom
-$110K

CASI Hedge Fund Activity: Q4 2018 in Review

54 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2018, worth a combined $45.9M — down 8.6% from $50.2M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of CASI and 3 opened new positions — a net loss of 9 holders — while 16 trimmed existing stakes and 22 added.

The largest buyer was Wellington Shields Capital Management, adding an estimated $1.09M. The largest seller was Royce & Associates, exiting entirely with an estimated $368K sold.

  • 54 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2018, down from 63 in Q3 2018.
  • Funds reported $45.9M of CASI Pharmaceuticals stock for Q4 2018, down 8.6% quarter-over-quarter.
  • 3 funds opened new CASI Pharmaceuticals positions in Q4 2018 and 12 closed out, a net change of -9 holders.
  • The largest CASI Pharmaceuticals buyer in Q4 2018 was Wellington Shields Capital Management, an estimated $1.09M added.
  • The largest CASI Pharmaceuticals seller in Q4 2018 was Royce & Associates, an estimated $368K sold.

Based on aggregated 13F filings for Q4 2018.